Acumen Stock Today

ABOS
 Stock
  

USD 5.22  0.13  2.55%   

Market Performance
13 of 100
Odds Of Distress
Over 51
Acumen Pharmaceuticals is selling at 5.22 as of the 10th of August 2022; that is 2.55 percent increase since the beginning of the trading day. The stock's lowest day price was 4.98. Acumen Pharmaceuticals has 51 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. Equity ratings for Acumen Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 11th of July 2022 and ending today, the 10th of August 2022. Click here to learn more.
Fiscal Year End
December
IPO Date
1st of July 2021
Category
Healthcare
ISIN
US00509G2093
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimers disease. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. The company has 40.47 M outstanding shares of which 949.42 K shares are presently shorted by private and institutional investors with about 2.92 trading days to cover. More on Acumen Pharmaceuticals

Moving together with Acumen Pharmaceuticals

0.74BLUBellus Health Aggressive PushPairCorr
0.89MBRXMoleculin Biotech Earnings Call  TodayPairCorr

Moving against Acumen Pharmaceuticals

0.83BBIBrickell Biotech Earnings Call  TomorrowPairCorr
0.79INMInmed Pharmaceuticals Fiscal Year End 23rd of September 2022 PairCorr
0.62BCLIBrainstorm Cell Earnings Call  This WeekPairCorr

Acumen Pharmaceuticals Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Acumen Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Acumen Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Acumen Pharmaceuticals is way too risky over 90 days horizon
Acumen Pharmaceuticals appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 329 K. Net Loss for the year was (82.74 M) with loss before overhead, payroll, taxes, and interest of (12.3 M).
Acumen Pharmaceuticals currently holds about 189.09 M in cash with (23.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.67.
Acumen Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 78.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022 - Yahoo Finance
Fama & French Classification
Average Analyst Recommendation
Analysts covering Acumen Pharmaceuticals report their recommendations after researching Acumen Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Acumen Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Acumen Pharmaceuticals. The Acumen consensus assessment is calculated by taking the average forecast from all of the analysts covering Acumen Pharmaceuticals.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Acumen Pharmaceuticals based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Acumen Pharmaceuticals financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares21.6 M20.1 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted21.6 M20.1 M
Significantly Up
Increasing
Slightly volatile
Total Assets248.5 M230.3 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities5.2 M5.1 M
Slightly Up
Increasing
Slightly volatile
Current Assets214.3 M198.7 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities5.2 M5.1 M
Slightly Up
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Acumen Pharmaceuticals' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldUndervalued
Acumen Pharmaceuticals (ABOS) is traded on NASDAQ Exchange in USA. It is located in 427 Park Street and employs 14 people. Acumen Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 211.25 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Acumen Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Acumen Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Acumen Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 40.47 M outstanding shares of which 949.42 K shares are presently shorted by private and institutional investors with about 2.92 trading days to cover. Acumen Pharmaceuticals currently holds about 189.09 M in cash with (23.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.67.
Check Acumen Pharmaceuticals Probability Of Bankruptcy
Ownership
Acumen Pharmaceuticals holds a total of fourty million four hundred seventy thousand outstanding shares. The majority of Acumen Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Acumen Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Acumen Pharmaceuticals. Please pay attention to any change in the institutional holdings of Acumen Pharmaceuticals as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Acumen Ownership Details

Acumen Stock Price Odds Analysis

What are Acumen Pharmaceuticals' target price odds to finish over the current price? In regard to a normal probability distribution, the odds of Acumen Pharmaceuticals jumping above the current price in 90 days from now is about 22.81%. The Acumen Pharmaceuticals probability density function shows the probability of Acumen Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.6501. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Acumen Pharmaceuticals will likely underperform. Additionally, the company has an alpha of 0.6349, implying that it can generate a 0.63 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 5.22HorizonTargetOdds Above 5.22
77.12%90 days
 5.22 
22.81%
Based on a normal probability distribution, the odds of Acumen Pharmaceuticals to move above the current price in 90 days from now is about 22.81 (This Acumen Pharmaceuticals probability density function shows the probability of Acumen Stock to fall within a particular range of prices over 90 days) .

Acumen Pharmaceuticals Historical Income Statement

Acumen Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Acumen's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Acumen Pharmaceuticals revenue and expense. Acumen Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
View More Fundamentals

Acumen Stock Against Markets

Picking the right benchmark for Acumen Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Acumen Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Acumen Pharmaceuticals is critical whether you are bullish or bearish towards Acumen Pharmaceuticals at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Acumen Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Analysis Now

   

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
All  Next Launch Module

Invested in Acumen Pharmaceuticals?

You need to understand the risk of investing before taking a position in Acumen Pharmaceuticals. The danger of trading Acumen Pharmaceuticals is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Acumen Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Acumen Pharmaceuticals. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Acumen Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. Note that the Acumen Pharmaceuticals information on this page should be used as a complementary analysis to other Acumen Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Acumen Stock analysis

When running Acumen Pharmaceuticals price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Is Acumen Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acumen Pharmaceuticals. If investors know Acumen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acumen Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
206.2 M
Return On Assets
-0.12
Return On Equity
-0.73
The market value of Acumen Pharmaceuticals is measured differently than its book value, which is the value of Acumen that is recorded on the company's balance sheet. Investors also form their own opinion of Acumen Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Acumen Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acumen Pharmaceuticals' market value can be influenced by many factors that don't directly affect Acumen Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acumen Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Acumen Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acumen Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.